Pfizer Inc. is cutting at least another $1.2 billion from its spending while the company searches for its next big hit after the failure of its obesity pill. Goldman Sachs Healthcare Analyst Asad Haider has more on the story and what to expect from Pfizer. (Source: Bloomberg)
